AstraZeneca PLC (NASDAQ:AZN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. AstraZeneca PLC (NASDAQ:AZN) and Revna Biosciences have succeeded in expanding access to EGFR-targeted lung cancer medication in Ghana, achieving a significant milestone since their collaboration began in April 2025. AstraZeneca PLC (NASDAQ:AZN)’s targeted therapy for patients with EGFR-mutated lung cancer marks an improvement in access to treatment in sub-Saharan Africa.Revna Biosciences and AstraZeneca Increase Access to Lung Cancer Treatment in Ghana

Iulian Valentin/Shutterstock.com

The partnership made it possible for leading cancer centers to incorporate EGFR biomarker testing into their diagnostic processes, which helped them make more accurate treatment choices. Revna organized a training workshop and strategic symposium to improve clinical processes and diagnostic skills. Future research and clinical decision-making are supported by real-time data integration.

AstraZeneca PLC (NASDAQ:AZN)’s Dr. Khomotso Mashilane noted the significance of merging diagnostics with targeted treatments. Revna CEO Dr. Derrick Edem Akpalu addressed the ecosystem’s importance in removing access obstacles. Dr. Preetivi Ellis, a co-founder, stressed how the work is transforming treatment for patients today and developing the genomic foundation for care in the future. It is one of the Best Weight Loss Stocks.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.